Schizophrenia, tardive dyskinesia, and brain GABA

Area of Science:

• Neuroscience
• Psychiatry
• Biochemistry

Background:

• Gamma-aminobutyric acid (GABA) is a key inhibitory neurotransmitter in the brain.
• Previous research suggested a potential role for GABAergic dysfunction in schizophrenia.
• Investigating neurotransmitter levels is crucial for understanding schizophrenia's neurobiology.

Purpose of the Study:

• To measure GABA and other amino compound levels in specific brain regions and cerebrospinal fluid (CSF) of schizophrenia patients.
• To determine if GABA deficiency is associated with schizophrenia or neuroleptic-induced tardive dyskinesia.
• To re-evaluate earlier findings on GABA levels in schizophrenia.

Main Methods:

• Autopsied brain tissue from 18 schizophrenia patients and controls were analyzed for GABA and amino compounds.
• Cerebrospinal fluid (CSF) GABA concentrations were measured in living schizophrenia patients and controls.
• High-performance liquid chromatography was used for amino compound quantification.

Main Results:

• No significant deficiency of GABA was found in five specific brain regions (frontal cortex, caudate nucleus, putamen, nucleus accumbens, medial dorsal thalamus) of deceased schizophrenia patients.
• GABA concentrations in the CSF of living schizophrenia patients were not lower than in controls.
• The study did not replicate previous findings of low GABA in the nucleus accumbens and thalamus in some schizophrenia patients.

Conclusions:

• The current neurochemical findings do not support the hypothesis of GABAergic neuronal hypofunction in the etiology of schizophrenia.
• Evidence does not link GABA deficiency to neuroleptic-induced tardive dyskinesia.
• Further research may be needed to explore other neurochemical pathways in schizophrenia.